We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+28.71%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.61B
AUM Growth
+$255M
Cap. Flow
+$47.3M
Cap. Flow %
1.31%
Top 10 Hldgs %
49.77%
Holding
131
New
18
Increased
36
Reduced
18
Closed
31

Top Buys

Rank Stock Value
1
MANE
Veradermics Inc
MANE
+$75.9M
2
CYTK icon
Cytokinetics
CYTK
+$39M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$32.4M
4
ERAS icon
Erasca
ERAS
+$29.4M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$23.3M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$76.1M
2
APLS
Apellis Pharmaceuticals
APLS
+$64.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$50.3M
4
RAPT
RAPT Therapeutics
RAPT
+$46.6M
5
ZYME icon
Zymeworks
ZYME
+$44.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.63%
2 Technology 3.69%
3 Communication Services 1.71%
4 Consumer Discretionary 0.77%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.44B
$532M 14.75%
10,825,013
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.94B
$265M 7.36%
3,186,830
-100,000
-3% -$7.92M
ERAS icon
3
Erasca
ERAS
$6.39B
$182M 5.04%
11,244,246
+2,486,997
+28% +$29.4M
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.68B
$140M 3.87%
4,430,263
-99,727
-2% -$2.88M
ONC
5
BeOne Medicines Ltd
ONC
$38.7B
$138M 3.83%
465,000
-35,000
-7% -$11.3M
TNGX icon
6
Tango Therapeutics
TNGX
$4.41B
$118M 3.28%
5,657,105
-2,508,269
-31% -$34.9M
BCAX
7
Bicara Therapeutics
BCAX
$1.84B
$115M 3.2%
5,802,970
+586,001
+11% +$10.1M
RVMD icon
8
Revolution Medicines
RVMD
$44B
$108M 3%
1,110,980
-224,095
-17% -$22.6M
ARWR icon
9
Arrowhead Research
ARWR
$12.4B
$101M 2.81%
1,615,476
+115,000
+8% +$7.28M
MANE
10
Veradermics Inc
MANE
$4.78B
$95.1M 2.64%
+1,505,374
New +$75.9M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.12B
$76.7M 2.13%
1,318,564
+505,803
+62% +$23.3M
OLMA icon
12
Olema Pharmaceuticals
OLMA
$1.05B
$70.9M 1.97%
4,756,949
+1,456,249
+44% +$32.4M
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.92B
$69.1M 1.92%
1,903,636
+396,000
+26% +$17.7M
LXRX icon
14
Lexicon Pharmaceuticals
LXRX
$1.1B
$69.1M 1.92%
44,303,518
+5,384,615
+14% +$7.83M
COGT icon
15
Cogent Biosciences
COGT
$7.24B
$65.8M 1.82%
1,709,279
+80,000
+5% +$2.95M
STOK icon
16
Stoke Therapeutics
STOK
$2.11B
$65M 1.8%
1,995,347
-252,000
-11% -$8.26M
RCUS icon
17
Arcus Biosciences
RCUS
$3.64B
$65M 1.8%
3,007,077
– –
GPCR icon
18
Structure Therapeutics
GPCR
$3.78B
$64M 1.78%
1,328,698
+250,000
+23% +$17.1M
IRON icon
19
Disc Medicine
IRON
$2.97B
$63.2M 1.75%
988,401
– –
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7.96B
$63.1M 1.75%
725,511
+225,536
+45% +$21.9M
SLDB icon
21
Solid Biosciences
SLDB
$826M
$55.4M 1.53%
7,690,405
– –
SEPN
22
Septerna Inc
SEPN
$1.75B
$48.1M 1.33%
2,000,000
– –
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
$41.8M 1.16%
1,053,464
-2,974,053
-74% -$76.1M
SYRE icon
24
Spyre Therapeutics
SYRE
$9.25B
$41.3M 1.14%
818,598
– –
CYTK icon
25
Cytokinetics
CYTK
$10.4B
$40.5M 1.12%
+613,952
New +$39M
1
2 3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q1 2026 Portfolio in Review

As of Q1 2026, Siren LLC held 131 positions worth $3.61B, up 7.6% from $3.35B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Siren LLC's Q1 2026 filing shows 18 new, 36 increased, 18 reduced and 31 closed positions. Its largest new stake was Veradermics Inc: 1,505,374 shares worth $95.1M. The largest sale was Centessa Pharmaceuticals, an estimated $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q1 2026 buy was Veradermics Inc: 1,505,374 shares worth $95.1M.
  • Siren LLC added most to Olema Pharmaceuticals in Q1 2026, an estimated $32.4M increase.
  • Siren LLC's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $76.1M.
  • Siren LLC fully exited Apellis Pharmaceuticals in Q1 2026, selling an estimated $64.8M.
  • Siren LLC's ten largest holdings make up 50% of its $3.61B portfolio in Q1 2026.
  • Siren LLC opened 18 new positions and closed 31 in Q1 2026.
  • Siren LLC's portfolio value rose 7.6% quarter-over-quarter to $3.61B.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.